Document is current
Any future updates will be listed below
-
Authors
Genova, Elena
Rispoli, Paola
Fengming, Yue
Kohei, Johkura
Bramuzzo, Matteo
Bulla, Roberta
Lucafò, Marianna
Ferraro, Rosalba Monica
Decorti, Giuliana
Stocco, Gabriele
-
Funding
Funding for this research was provided by:
Institute for Maternal and Child Health -- IRCCS “Burlo Garofolo” (RC 44/22)
Institute for Maternal and Child Health -- IRCCS “Burlo Garofolo” (RC 07/14)
- License Information
-
More Information
Article History
Received: 30 August 2024
Accepted: 20 November 2024
First Online: 18 December 2024
Declarations
:
: The study was approved by the Ethical Committee of the Institute of Maternal and Child Health IRCCS Burlo Garofolo, with approval number 1556 (internal ID of the study RC 07/14 and RC 44/22). Title of the approved project: “ Patient-derived induced pluripotent stem cells for personalizing therapy: the paradigm of thiopurine pancreatitis in Crohn’s disease” and “Comparison of 2D and 3D patient-derived pancreatic exocrine models for the study of thiopurine induced pancreatitis in pediatric IBD patients: an innovative approach therapy personalization”; Name of the institutional approval committee: Ethical Committee of the Institute of Maternal and Child Health IRCCS Burlo Garofolo (Trieste, Italy); Approval number: 1556; Date of approval: 14.07.2014.
: Obtained from all subjects involved in the study.
: The authors declare that they have no competing interests.
